Expression and release of adhesion molecules by human acute myelogenous leukemia blasts.

Abstract:

:The expression and release of adhesion molecules by acute myelogenous leukemia (AML) blasts was investigated in vitro. For most patients AML blasts expressed relatively low levels of membrane-bound L-selectin and Intercellular adhesion molecule 1 (ICAM-1), but their soluble forms were detected in the supernatants for the majority of patients when AML blasts were cultured in vitro. These in vitro levels of SL-selectin and sICAM-1 were considerably lower than the normal serum levels. Divergent and relatively small alterations in SL-selectin and sICAM-1 levels were usually observed when exogenous growth factors were present during AML blast culture, whereas increased SL-selectin levels were observed after coculture of AML blasts and normal leucocytes. E- and P-selectin were neither expressed nor released by AML blasts. We conclude that AML blasts are a source of soluble adhesion molecules.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Bruserud O,Ulvestad E

doi

10.1016/s0145-2126(98)00156-8

keywords:

subject

Has Abstract

pub_date

1999-02-01 00:00:00

pages

149-57

issue

2

eissn

0145-2126

issn

1873-5835

pii

S0145212698001568

journal_volume

23

pub_type

杂志文章
  • Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.

    abstract::Imatinib mesylate, a Bcr/Abl tyrosine kinase inhibitor, is widely used in treating chronic myeloid leukemia. However, drug-resistance of leukemia cells becomes an emergent problem. Herein, various flavonoids were screened for applicability in leukemia treatment, and 3-hydroxyflavone (3-HF) was found to be most effecti...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.05.018

    authors: Kim JH,Song M,Kang GH,Lee ER,Choi HY,Lee C,Kim JH,Kim Y,Koo BN,Cho SG

    更新日期:2012-09-01 00:00:00

  • Incidence of 5' bcl-2 rearrangement in patients with B cell chronic lymphocytic leukemia from India.

    abstract::The incidence of B cell chronic lymphocytic leukemia (B-CLL) is lower in Asian countries, including India, when compared with Western countries. The bcl-2 gene rearrangement was restricted to the 5' region and seen in only one of the 20 Indian patients analyzed. The incidence remains similar to that reported from West...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(96)00036-7

    authors: Parikh PM,Desai S,Naresh KN,Shakuntaka B,Laxminarayan K,Nair CN,Ladanyi M,Soman CS,Advani SH,Chaganti RS

    更新日期:1996-09-01 00:00:00

  • The intracellular location of terminal transferase does not vary with cell cycle stage.

    abstract::The biochemical activity of terminal transferase (TdT) in the thymocytes of leukemic AKR mice has no relationship to cell cycle stage, unlike the activity of replicative DNA polymerase which increases during the period of DNA synthesis. Moreover, such assays of DNA polymerase alpha reveal a shift in enzyme activity fr...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90082-1

    authors: Barr RD,Barresi T,Koekebakker M,Sarin PS

    更新日期:1984-01-01 00:00:00

  • Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV).

    abstract::Cell-mediated natural cytotoxicity (CMNC) of fresh or long-term cultured lymphocytes collected from HTLV-positive patients or infected in vitro with the virus, was tested against K562 target cells. Severe depression of reactivity was found in fresh lymphocytes of three patients with advanced disease, in 12 in vitro es...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90056-6

    authors: De Vecchis L,Graziani G,Macchi B,Grandori C,Pastore S,Popovic M,Gallo RC,Bonmassar E

    更新日期:1985-01-01 00:00:00

  • HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.

    abstract::We analyzed the biological activity of HA14-1, a small organic compound inhibitor of Bcl-2, against established leukaemia cell lines and blasts from acute myeloid leukaemia (AML) patients. HA14-1 had a potent killing activity against the leukaemia cell line that expressed endogenous or ectopic Bcl-2. This activity was...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.010

    authors: Oliver L,Mahé B,Gréé R,Vallette FM,Juin P

    更新日期:2007-06-01 00:00:00

  • Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2'-deoxycytidine.

    abstract::5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(90)90067-j

    authors: Momparler RL,Laliberté J

    更新日期:1990-01-01 00:00:00

  • Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

    abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...

    journal_title:Leukemia research

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.leukres.2013.01.004

    authors: Adès L,Sekeres MA,Wolfromm A,Teichman ML,Tiu RV,Itzykson R,Maciejewski JP,Dreyfus F,List AF,Fenaux P,Komrokji RS

    更新日期:2013-06-01 00:00:00

  • Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging.

    abstract::Assessment of treatment response in acute leukemia is routinely performed after therapy via bone marrow biopsy. We investigated the use of positron emission tomography (PET) for early assessment of treatment response in patients with acute myeloid leukemia (AML), using the proliferation marker 3'-deoxy-3'-[(18)F]fluor...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.06.010

    authors: Vanderhoek M,Juckett MB,Perlman SB,Nickles RJ,Jeraj R

    更新日期:2011-03-01 00:00:00

  • Myelodysplastic syndrome associated with Griscelli syndrome.

    abstract::Myelodysplastic syndrome (MDS) in children has been reported to be associated with various constitutional anomalies; however, it has not been described previously in patients with Griscelli syndrome (GS). In this report, we present a case with GS and refractory anemia with an excess of blasts. We believe that careful ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00075-7

    authors: Cetin M,Hiçsönmez G,Göğüş S

    更新日期:1998-09-01 00:00:00

  • Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma.

    abstract::The serum levels of interleukin 6 (IL6) are known to be elevated in two diseases of the elderly age, myelodysplastic syndrome (MDS) and multiple myeloma (MM). Authors suppose that one of the possible causes of this elevation could be a difference between these patients and healthy subjects in the frequency of polymorp...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2009.03.009

    authors: Aladzsity I,Kovács M,Semsei A,Falus A,Szilágyi A,Karádi I,Varga G,Füst G,Várkonyi J

    更新日期:2009-11-01 00:00:00

  • 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.

    abstract::Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.12.017

    authors: Kim WS,Lee MJ,Kim DH,Lee JE,Kim JI,Kim YC,Song MR,Park SG

    更新日期:2013-04-01 00:00:00

  • Induction of differentiation of myelogenous leukemia cells by humulone, a bitter in the hop.

    abstract::The active form of vitamin D, 1alpha,25-dihydroxyvitamin D3 (VD3), inhibits proliferation and induces differentiation of myelomonocytic leukemia cells, but its clinical use is limited by the adverse effect of hypercalcemia. VD3 mobilizes calcium stores from bone by inducing the dissolution of bone mineral and matrix. ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/s0145-2126(98)00046-0

    authors: Honma Y,Tobe H,Makishima M,Yokoyama A,Okabe-Kado J

    更新日期:1998-07-01 00:00:00

  • Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1.

    abstract::Selective inhibition of the BCR/ABL tyrosine kinase by imatinib (STI571, Glivec/Gleevec) is the therapeutic strategy in patients with chronic myelogenous leukemia (CML). Despite significant hematologic and cytogenetic responses with imatinib, mainly due to the mutations in the Abl kinase domain, resistance occurs in p...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.11.007

    authors: Arunasree KM,Roy KR,Anilkumar K,Aparna A,Reddy GV,Reddanna P

    更新日期:2008-06-01 00:00:00

  • The incidence of hybrid acute leukaemias.

    abstract::During a 4-yr period, 292 patients with acute leukaemia were studied using morphology, cytochemistry and immunologic reagents to determine the cell lineage of the leukaemia. One hundred and sixty-three cases were shown to be acute lymphoblastic leukaemia (ALL), 127 acute myeloblastic leukaemia (AML) and two cases (0.6...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90002-1

    authors: Ruiz-Argüelles GJ,Lobato-Mendizábal E,Marín-López A

    更新日期:1988-01-01 00:00:00

  • Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?

    abstract:BACKGROUND:Analyses suggest MDS patients with higher serum ferritin levels (SF) have inferior overall survival (OS), in one study across MDS subtypes. Multiple analyses suggest those with high SF receiving iron chelation therapy (ICT) have superior OS, but which MDS subtypes benefit from ICT remains undefined. METHODS...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.11.005

    authors: Wong SA,Leitch HA

    更新日期:2018-01-01 00:00:00

  • 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.

    abstract::3q26.2/EVI1 rearrangements resulting in EVI1 overexpression play an important role in leukemogenesis and are associated with treatment resistance and a poorer prognosis in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia and BCR-ABL negative myeloproliferative neoplasms. In this...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2017.12.004

    authors: Hu Z,Hu S,Ji C,Tang Z,Thakral B,Loghavi S,Medeiros LJ,Wang W

    更新日期:2018-02-01 00:00:00

  • Good riddance to the term "refractory anemia" in myelodysplastic syndromes.

    abstract::The term "refractory anemia" was used in 1937 by Cornelius Parker Rhoads to describe patients whose anemia did not improve after treatment with liver extract or iron salts, and this term has been used to denote patients with certain subtypes of myelodysplastic syndromes (MDS) since the 1976 and 1982 French-American-Br...

    journal_title:Leukemia research

    pub_type: 历史文章,杂志文章

    doi:10.1016/j.leukres.2016.10.007

    authors: Steensma DP

    更新日期:2016-12-01 00:00:00

  • Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy.

    abstract::Useful prognostic markers for patients with diffuse large B cell lymphoma (DLBCL) have been reported. To identify which biomarker best predicts the prognosis of patients with DLBCL, we performed a retrospective study that included 319 DLBCL patients who had received rituximab, cyclophosphamide, doxorubicin, vincristin...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2015.08.016

    authors: Miyashita K,Tomita N,Taguri M,Suzuki T,Ishiyama Y,Ishii Y,Nakajima Y,Numata A,Hattori Y,Yamamoto W,Miyazaki T,Tachibana T,Takasaki H,Matsumoto K,Hashimoto C,Takemura S,Yamazaki E,Fujimaki K,Sakai R,Motomura S,Ishi

    更新日期:2015-08-29 00:00:00

  • Balance of NF-kappaB and p38 MAPK is a determinant of radiosensitivity of the AML-2 and its doxorubicin-resistant cell lines.

    abstract::This study investigated radioresistance mechanisms in the doxorubicin-resistant acute myelogenous leukemia (AML)-2/DX100. AML-2/DX100 also showed resistance to radiation. AML-2/DX100 characterized by down-regulated catalase expression was supersensitive to exogenous hydrogen peroxide whereas they increased defense mec...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2006.11.006

    authors: Choi CH,Xu H,Bark H,Lee TB,Yun J,Kang SI,Oh YK

    更新日期:2007-09-01 00:00:00

  • Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.

    abstract::We have recently established the MV4-11 acute myelogenous leukemia (AML) subline, designated as MV4-11 TP53 R248W, which possesses a missense mutation (CGG→TGG; R248W) in the TP53 gene, leading to inactivation of this transcription factor. DNA methyltransferase (DNMT) inhibitor 5-Aza-2'-deoxycytidine (5-AzadC) induced...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2011.04.004

    authors: Nishioka C,Ikezoe T,Yang J,Udaka K,Yokoyama A

    更新日期:2011-07-01 00:00:00

  • Effect of prostaglandin E2 on gamma-interferon and 1,25(OH)2D3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation.

    abstract::The effect of prostaglandin E2 (PGE2) on the reduction of c-myc expression during the differentiation of the human leukemic cell line, HL-60, was examined. PGE2, a potent inducer of intracellular cyclic AMP (cAMP) in HL-60 cells, augmented monocyte-associated cell surface antigens induced by human gamma-interferon (IF...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90090-2

    authors: Matsui T,Nakao Y,Koizumi T,Katakami Y,Takahashi R,Mihara K,Sugiyama T,Fujita T

    更新日期:1988-01-01 00:00:00

  • Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

    abstract::C-kit, a tyrosine kinase receptor, is expressed on most myeloid blasts and is thought to be important in the pathogenesis of AML. Activation of the c-kit receptor leads to phosphorylation and activation of downstream signaling proteins, which are important for cell survival and proliferation. Here, we discuss the prog...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2007.08.019

    authors: Advani AS,Rodriguez C,Jin T,Jawde RA,Saber W,Baz R,Kalaycio M,Sobecks R,Sekeres M,Tripp B,Hsi E

    更新日期:2008-06-01 00:00:00

  • miRNA mediated up-regulation of cochaperone p23 acts as an anti-apoptotic factor in childhood acute lymphoblastic leukemia.

    abstract::p23 is a heat shock protein 90 (Hsp90) cochaperone that plays a significant role in estrogen receptor (ER) alpha signal transduction and telomerase activity; it is up-regulated in several cancers. Recent studies have found that high level of p23 may promote tumor progression and poor prognosis in breast cancer patient...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2012.05.003

    authors: Liu X,Zou L,Zhu L,Zhang H,Du C,Li Z,Gao C,Zhao X,Bao S,Zheng H

    更新日期:2012-09-01 00:00:00

  • Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance.

    abstract::The ubiquitin-proteasome system (UPS) plays a major role in the homeostasis of cellular protein. We demonstrate that each of the major hematologic diseases (AML, ALL, and MDS) has a specific and different plasma profile of UPS protein and enzymatic activities. While high levels of proteasome and ubiquitin proteins and...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.09.009

    authors: Ma W,Kantarjian H,Zhang X,Wang X,Estrov Z,O'Brien S,Albitar M

    更新日期:2011-04-01 00:00:00

  • Myelodysplastic syndromes in patients under 50 years old: a single institution experience.

    abstract::We report on our experience relating to 62 patients with myelodysplastic syndrome (MDS) aged less than 50 years, seen at our Institution and conservatively treated from July 1983 to December 2000. Patients demographics and clinical features at diagnosis were analysed for their prognostic value on survival and on risk ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2005.01.003

    authors: Breccia M,Mengarelli A,Mancini M,Biondo F,Gentilini F,Latagliata R,Mandelli F,Alimena G

    更新日期:2005-07-01 00:00:00

  • Characterization of the AKR thymic microenvironment and its influence on thymocyte differentiation and lymphoma development.

    abstract::The thymic stroma has long been implicated in AKR thymic leukaemia. In this study an extensive panel of monoclonal antibodies was used to investigate changes in the AKR thymic microenvironment, in parallel with thymocyte differentiation of normal (2 month), preleukaemic (5-7 month) and leukaemic (> 7 month) mice. We f...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(95)00102-6

    authors: Davey GM,Tucek-Szabo CL,Boyd RL

    更新日期:1996-10-01 00:00:00

  • Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep.

    abstract::Delta retrovirus-mediated leukemogenesis is dependent on the oncogenic potential of Tax. It is not clear, however, whether Tax-specific immune responses play a role in leukemia onset and progression. Using the BLV-associated leukemia model in sheep, we found that Tax-specific cytotoxic responses induced by DNA immuniz...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/j.leukres.2010.06.003

    authors: Van den Broeke A,Oumouna M,Beskorwayne T,Szynal M,Cleuter Y,Babiuk S,Bagnis C,Martiat P,Burny A,Griebel P

    更新日期:2010-12-01 00:00:00

  • Granulocyte functions during maturation of human promyelocytic leukemia cells.

    abstract::Human promyelocytic leukemia cells (HL-60) mature into functional granulocytes in response to in vitro treatment with several classes of chemical agents. Compounds that increase intracellular adenosine 3':5' -cyclic monophosphate induce a modified program of maturation in which the cells demonstrate functional propert...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(85)90311-x

    authors: Chaplinski TJ,Sloan GJ,Niedel JE

    更新日期:1985-01-01 00:00:00

  • Deoxycytidylate deaminase activity in lymphoproliferative disorders.

    abstract::The activity of dCMPase has been measured in cell extracts from human lymphoproliferative disorders. The highest levels occurred in T helper-CLL and Thy-ALL, but high levels were also found in C-ALL, NPDLL transforming to DHL, DPDLL and DHL. A range of enzyme activities was found in the majority of types examined, wit...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(84)90040-7

    authors: Ellims PH,Medley G

    更新日期:1984-01-01 00:00:00

  • Activation of Ha-ras in human chronic granulocytic and chronic myelomonocytic leukaemia.

    abstract::DNAs from chronic granulocytic leukaemia (CGL) and chronic myelomonocytic leukaemia (CMML) were assayed for transforming genes by transfection into NIH 3T3 cells. Foci DNA was tagged with a geneticin-resistance cosmid, then followed through a drug selection and tumorigenicity assay. Activated Ha-ras genes, with point ...

    journal_title:Leukemia research

    pub_type: 杂志文章

    doi:10.1016/0145-2126(88)90033-1

    authors: Gow J,Hughes D,Farr C,Hamblin T,Oscier D,Brown R,Padua RA

    更新日期:1988-01-01 00:00:00